Research programme: endoglin antibodies - Tracon
Latest Information Update: 24 Mar 2025
At a glance
- Originator TRACON Pharmaceuticals
- Class Monoclonal antibodies
- Mechanism of Action ENG protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Fibrosis
Most Recent Events
- 12 Nov 2024 Discontinued - Preclinical for Fibrosis in USA (Parenteral) (Tracon pharmaceuticals website, November 2024)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Fibrosis in USA (Parenteral)
- 25 Jan 2016 Preclinical trials in Fibrosis in USA (Parenteral)